Study

EORTC-62024

Intermediate and high risk localized,completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor : a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery.

Study documentation Back to result

Trial Status

All trial activities ended

Dates

Date of activation: 08-Dec-2004
Date Step1 close: 20-Oct-2008

Data management at EORTC

Yes

Design

Phase 3
Randomized open label

Targeted Sample size

EORTC Groups: 350 - All Groups: 900

Protocol summary

http://clinicaltrials.gov/study/NCT00103168

NCT number

NCT00103168

EudraCT

2004-001810-16